Tuberculosis in Canada: a century of progress.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to G L Gale.
Explore the source record for details and available documents.
Cultures from 80 out of 1667 patients (4.8%) admitted consecutively to a tuberculosis hospital grew atypical mycobacteria. With four strict criteria it was concluded that the mycobacteria isolated were the cause of the disease in 47 of these patients. The majority of these organisms were resistant to most, and in seven cases to all, of the antituberculous drugs. Ten patients responded poorly to treatment and 14 patients (30%) died, 8 of these from uncontrollable pulmonary infection with the atypical organisms. It is suggested that a recent, simplified classification of mycobacteria proposed by Runyon be adopted.
A comparison was made of the therapeutic efficiency and tolerance of rifampin-based regimens and that of the standard triple-drug combination in the treatment of 92 newly diagnosed cases of pulmonary tuberculosis. The three drug regimens investigated were: A, rifampin-INH; B, rifampin-INH-streptomycin; and C, INH-PAS-streptomycin. Therapeutic progress was measured in terms of sputum conversion on culture and microscopy. The rifampin combinations produced a somewhat earlier sputum conversion. With regimens containing this potent antibiotic the phenomenon of microscopically-positive but culture-negative specimens was more frequently observed. The tolerance exhibited to the rifampin regimens was far greater than that to the conventional triple-drug combination. Nevertheless, periodic laboratory examinations are essential during rifampin therapy for safe utilization of the drug. An incidental finding of this study was the increase in primary resistance to streptomycin particularly among recent immigrants to Canada.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.